Viewing nowCombinationJanugriptin Duo XR Sustained Release Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Sears Pharmaceutical Co., Ltd.

MFDS item code 202300616 · Approved 2023.02.17 · Insurance code 689001780
Improvement of glycemic control in type 2 diabetes
This medication is intended to assist patients with type 2 diabetes in controlling their blood sugar levels. The components sitagliptin and metformin work together to effectively manage blood sugar. It is suitable for patients who are also following dietary and exercise regimens, helping to stabilize blood sugar levels. By taking it consistently, patients can improve their blood sugar control and significantly aid in health management.
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients currently receiving immediate-release metformin at a dose of 850 mg or 1000 mg twice daily may start this drug at a dose of 2 50/1000 mg extended-release tablets once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the initial dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.
This medication is used for the treatment of diabetes and assists in blood sugar control. However, it may cause allergic reactions in some patients, so if symptoms such as a skin rash, difficulty breathing, or swelling of the face or throat occur within three months after starting the medication, it should be discontinued immediately and a doctor consulted. There is a risk of pancreatitis, an inflammation of the pancreas, with this medication, so patients should notify their healthcare provider immediately if abdominal pain, vomiting, or severe abdominal discomfort occur. Additionally, one of the components in this medication should not be administered to patients with severely impaired kidney function, and patients with reduced kidney function should undergo regular kidney function tests. Acute diseases that can affect kidney function, such as severe infections, dehydration, acute heart failure, and acute myocardial infarction, should not be treated with this medication. In particular, the medication should be temporarily discontinued before and after examinations using iodine contrast media, and reinitiated only after confirming normal kidney function. Women who are pregnant or may become pregnant, as well as nursing mothers, should avoid taking this medication for safety. This medication can cause hypoglycemia, so caution should be exercised when skipping meals or engaging in vigorous exercise, and the dosage should be adjusted under the direction of a physician if taken with other hypoglycemic agents to reduce the risk of hypoglycemia. Moreover, this medication may lower vitamin B12 levels, so regular blood tests to check vitamin B12 levels are recommended for long-term use. Excessive alcohol consumption can increase the risk of side effects from this medication, thus alcohol should be avoided during treatment. If surgery is planned, this medication should be discontinued 48 hours prior to the procedure, and resumed once normal oral intake has returned and kidney function has been confirmed to be normal. While taking this medication, regular blood sugar tests and kidney function checks should be conducted to continuously monitor health status, and any unusual symptoms should prompt immediate consultation with a physician.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so to ensure safe storage, it should be kept in a sealed container. It is advisable to store it at room temperature between 1 and 30 degrees Celsius. This will help maintain its efficacy and prevent degradation.
Bright green oval sustained release film-coated tablets
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Sears Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.